 xxxd135xxx  hoechst ag.  hoechst is developing  xxxd135xxx , a synthetic flavonoid based on an extract from an indian plant, for the potential treatment of cancer.  xxxd135xxx , a cyclin-dependent kinase inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660]. a phase ii trial, in collaboration with the national cancer institute, has commenced at the university of chicago medical center, which involves patients with high or intermediate-grade lymphoma or multiple myeloma [272937], [277372]. in ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent  xxxg410xxx  inhibition associated with apoptotic changes was seen at concentrations greater than 100 nm of  xxxd135xxx . in vitro pharmacokinetic studies have shown that  xxxd135xxx  undergoes hepatic biotransformation to its corresponding glucoronide by  xxxd3476xxx  glucoronosyltransferases [283791].  xxxd135xxx  inhibits cdk with an ic50 value of 0.4 mm [285707]. preclinical toxicology studies in rats and dogs demonstrated dose-related leukopenia and drug-related lesions in the thymus, spleen and bone marrow. the gastrointestinal and bone marrow toxicity was dose-limiting [178579]. hoechst marion roussel expects to launch  xxxd135xxx  in the year 2001, with potential sales in excess of dm 750 million [288651].